541 ctDNA as a potential surrogate biomarker for response to combination vilastobart and atezolizumab in heavily pretreated microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (NCT04896697)
Regular and Young Investigator Award Abstracts | November 10, 2025 | Volume: No volume available | Issue: No issue available | Pages: A617-A617
10.1136/jitc-2025-sitc2025.0541